Welcome to our dedicated page for Agenus SEC filings (Ticker: AGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Agenus Inc. (NASDAQ: AGEN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a publicly traded immuno-oncology developer. As a filer under the Securities Exchange Act of 1934, Agenus uses Forms 8-K, 10-Q, 10-K and proxy materials to report financial results, clinical and corporate milestones, and shareholder actions related to its cancer immunotherapy programs.
Recent Form 8-K filings illustrate how these documents track material events. Agenus has furnished quarterly financial results for periods in 2025, reported on its annual meeting of stockholders and voting outcomes on director elections and equity plans, and described a promissory note agreement with a Zydus Lifesciences subsidiary tied to the planned sale of its Emeryville and Berkeley biologics manufacturing facilities. Other 8-Ks outline progress on the broader asset purchase, stock purchase and license agreements with Zydus, including updates on the Committee on Foreign Investment in the United States (CFIUS) review process.
For investors analyzing Agenus, periodic reports such as Forms 10-Q and 10-K (when available) are central to understanding the company’s financial condition, risk factors and research and development focus in immuno-oncology. These filings typically discuss the BOT+BAL clinical program, broader pipeline of antibody therapeutics, adoptive cell therapies and adjuvants, and the company’s development capabilities and collaborations.
On Stock Titan, each new Agenus filing is captured from EDGAR and paired with AI-powered summaries designed to highlight the most important points—such as key terms of financing arrangements, updates on the Zydus collaboration, or changes in capital structure. Users can also review Forms 4 and related ownership reports to monitor insider transactions in AGEN shares. This centralized view helps readers navigate complex SEC documents and quickly identify information relevant to Agenus’ immuno-oncology strategy, clinical progress and corporate governance.
Agenus (NASDAQ: AGEN) filed a routine Form 4 disclosing an equity award to Christine M. Klaskin, the company’s Principal Financial and Accounting Officer. On 06/17/2025, Klaskin was granted 7,250 stock options with a strike price of $3.02 per share under the 2019 Amended & Restated Equity Incentive Plan. The award had been approved by shareholders the same day. One-third of the options vest on 05/28/2026, with the balance vesting in equal quarterly installments thereafter, and the options expire on 05/28/2035. No shares were sold or otherwise disposed of, and Klaskin’s beneficial ownership increased by the option amount. The transaction appears to be a standard, non-material compensation grant rather than a market-moving insider trade.